ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: PDF (Size: 530K)  | Related Articles | Citation Tracking

Paroxetine and amitriptyline in the treatment of depression in general practice
P. E. Christiansen 1 , 7 , K. Behnke 2 , C. H. Black 3 , J. K. Öhrström 4 , H. Bork-Rasmussen 5 J. Nilsson 6
  1 Specialist in Psychiatry, Aarhus, Denmark   2 Specialist in Psychiatry, Frederiksberg, Denmark   3 Novo Nordisk A/S, Bagsvaerd, Denmark   4 Novo Nordisk Pharmaceuticals Inc., Princeton, USA   5 General Practitioner, Bylderup Bov, Denmark   6 Novo Nordisk Farmaka Danmark A/S, Bagsvaerd, Denmark
Correspondence to   7 Specialist in Psychiatry, Rosenkrantzgade 2, 2nd floor, DK-8000 Aarhus C, Denmark
Copyright 1996 Blackwell Munksgaard
KEYWORDS
paroxetine • amitripyline • depression

ABSTRACT

Christiansen PE, Behnke K, Black CH, Öhrström JK, Bork-Rasmussen H, Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996: 93: 158–163. © Munksgaard 1996.

A total of 144 outpatients in general practice in Denmark, aged 18–65 years and diagnosed as suffering from depression with a HAMD-17 score of 15 or more, were included in this 8-week double-blind, randomised, multicentre, controlled, parallel group comparison of paroxetine versus amitriptyline. The purpose of the study was primarily to evaluate efficacy and tolerance of treatment. In addition, focus was added on weight change and subjective well-being. The efficacy results showed equal effect of both drugs. However, paroxetine was tolerated better than amitriptyline, and this difference reached the level of significance when four non-evaluable patients were taken out of the analysis. Moreover, there was a significant weight increase in the amitriptyline group and no significant weight change in the paroxetine group. There was no difference between the groups as regards subjective well-being as measured by the VAS. In conclusion, paroxetine is an effective and well-tolerated antidepressant, and well-suited for the treatment of depression in general practice.


Accepted for publication June 6, 1995

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1600-0447.1996.tb10623.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Sign Up Now
Special Issue
CPSP

Free Access to Special Issue on BIPOLAR DISORDERS

This special issue of Clinical Psychology: Science and Practice features reviews of current evidence in the study of Bipolar Disorders with emphasis on the contributions of psychological science and implications for evidence-based practice. Commentaries by international experts provide a global, interdisciplinary context.

Read free special issue

Sign Up Now

Sign Up Now

Be the first to know about new research in your field

Sign up for FREE e-alerts from Wiley-Blackwell journals!

Sign Up Now

Special Issue
Personality and Mental Health

Personality and Mental Health
Volume 4
Issue 1


National Institute for Health and Clinical Excellence Guidelines for the Treatment of Antisocial Personality Disorder and Borderline Personality Disorder

Read the Special Issue
FREE online